The present review aimed to establish an understanding of the pathophysiology of
leptomeningeal disease as it relates to late-stage development among different cancer …

Background Glioblastoma (GBM) is the most common and aggressive primary malignant
brain tumor. Leptomeningeal spread (LMS) is a severe complication of GBM, raising …

Objective To perform a retrospective analysis examining the incidence and prognosis of
glioma patients with leptomeningeal disease (LMD) at Memorial Sloan Kettering Cancer …

Background: Leptomeningeal disease (LMD), also known as neoplastic meningitis,
leptomeningeal carcinomatosis, or carcinomatous meningitis, is a rare cancer complication …

Introduction Glioblastoma is an aggressive cancer with a notoriously poor prognosis. Recent
advances in treatment have increased overall survival, though this may be accompanied by …

Purpose To comprehensively investigate prognostic factors, including clinical and molecular
factors and treatment modalities, in adult glioma patients with leptomeningeal metastases …

Opinion statement Treatment options for leptomeningeal metastases are expanding with
greater tolerability and efficacy than in the past. Improved knowledge of molecular subtypes …

BACKGROUND Glioblastoma (GBM) is one of the most common and aggressive primary
malignant brain tumors with severe symptoms and a poor prognosis. Leptomeningeal …

In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been
shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in …

Approximately two-thirds of glioblastoma (GBM) patients progress to leptomeningeal spread
(LMS) within two years. While 90% of LMS cases are diagnosed during the progression …